PRKAA1 and breast carcinoma: In the present study, we observed that the combination of melatonin and doxorubicin reduced the level of AMPKα1, which acts as a critical survival factor for cancer cells; this phenomenon was seen in many different cancer cells, including breast cancer cells, and was also evident in cells subjected to combined treatment with melatonin and other cancer drugs.